2
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
44
Prostatic Neoplasms, Castration-Resistant
6
Neoplasm Metastasis
5
Metastatic Castration-resistant Prostate Cancer
4
Breast Neoplasms
4
Prostate Carcinoma Metastatic to the Bone
2
Neoplasms
2
Multiple Myeloma
2
Metastatic Castration-resistant Prostate Cancer (mCRPC)
2
Hormone Refractory Prostate Cancer
2
Carcinoma, Renal Cell
2
Carcinoma, Non-Small-Cell Lung
2
Bone Metastatic Castration-resistant Prostate Cancer
2
Thyroid Neoplasms
1
Prostate Cancer Metastatic to Bone
1
Prostate Adenocarcinoma
1
Pain
1
Metastatic Castration Resistant Prostate Cancer (mCRPC)
1
Metastatic Castrate Resistant Prostate Cancer (mCRPC)
1
Lymphatic Metastasis
1
Lung Neoplasms
1
Fractures, Bone
1
Fatigue
1
Castration-resistant Prostate Cancer
1
Castrate-Resistant Prostate Cancer
1
Bony Metastases From Castrate Refractory Prostate Cancer
1
Bone Neoplasms
1
Bone Metastases
1
Bone Diseases
1
Anatomic Stage IV Breast Cancer AJCC v8
1
Interventions
talazoparib
1
radium Ra 223 dichloride
1
olaparib
1
Pluvicto
1
Lutetium-177
1
Lutetium
1
CX 5461
1
BAY 2315497
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Metastatic Castration Resistant Prostate Cancer (mCRPC)
×
radium Ra 223 dichloride
×
Clear all
NCT04516161
2022-03-31
EPIX
Bayer
Completed
1,180 enrolled